BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), versus ($0.34) reported last year. Revenue for the quarter came in at $47.2 million, versus $4 million reported last year.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.